These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23374617)

  • 1. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents.
    Bowlin SJ; Xia F; Wang W; Robinson KD; Stanek EJ
    Mayo Clin Proc; 2013 Feb; 88(2):139-48. PubMed ID: 23374617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
    Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
    Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
    Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
    Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003.
    Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
    J Clin Pharm Ther; 2006 Feb; 31(1):73-82. PubMed ID: 16476123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically important drug-drug interactions in primary care.
    Dhabali AA; Awang R; Zyoud SH
    J Clin Pharm Ther; 2012 Aug; 37(4):426-30. PubMed ID: 22081958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions with solid tumour-targeted therapies.
    Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
    Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions between oral antiepileptics and oral anticancer drugs: implications to clinicians.
    Cheung YT; Yap KY; Chui WK; Chan A
    Eur Neurol; 2010; 64(2):88-94. PubMed ID: 20606454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice.
    Galatti L; Mazzaglia G; Greco A; Sessa E; Cricelli C; Schito GC; Nicoletti G; Spina E; Caputi AP
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):422-8. PubMed ID: 17323404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.
    Azam C; Claraz P; Chevreau C; Vinson C; Cottura E; Mourey L; Pouessel D; Guibaud S; Pollet O; Le Goff M; Bardies C; Pelagatti V; Canonge JM; Puisset F
    Eur J Clin Pharmacol; 2020 Apr; 76(4):579-587. PubMed ID: 31932871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
    Breccia M; Alimena G
    Leuk Res; 2013 Jun; 37(6):713-20. PubMed ID: 23473918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.
    Song X; Varker H; Eichelbaum M; Stopfer P; Shahidi M; Wilson K; Kaiser R; Finnern HW
    Lung Cancer; 2011 Oct; 74(1):103-11. PubMed ID: 21382644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
    Spigel D; Jones S; Hainsworth J; Infante J; Greco FA; Thompson D; Doss H; Burris H
    Cancer Invest; 2011 May; 29(4):308-12. PubMed ID: 21469980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
    Czaja AS; Valuck R
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.